Gland Pharma Limited is launching an IPO on November 9, 2020. Here are all the important details of the IPO.
How to Apply for Gland Pharma IPO?
You can apply for Gland Pharma IPO on Groww easily via UPI. Go to IPO ( login to your account). There you would be able to see the list of all open IPOs. Select Gland Pharma IPO and click on ‘Apply’. You would be able to invest in this IPO on November 09, 2020. IPO is also live on Groww app as well. To access IPOs you can go the to stocks tab and see the list of upcoming IPOs under the top losers card. Please update your app to the latest version to view the IPO option.
IPO Date | November 09, 2020 to November 11, 2020 |
Issue Type | Book Built Issue IPO |
Issue Size | 43,196,968 Equity Shares of Re.1 totaling up to Rs.6,459.55 Crore |
Fresh Issue | 8,333,333 Equity Shares of Re.1 totaling up to Rs.1,250.00 Crore |
Offer for Sale | 34,863,635 Equity Shares of Re.1 totaling up to Rs. 5,229.55 Crore |
Face Value | Re.1 per equity share |
IPO Price | Rs.1490 to Rs.1500 per equity share |
Market Lot | 10 Shares |
Min Order Quantity | 10 Shares |
Listing At | BSE, NSE |
Companies | Type | Bidding Dates | |
Regular | Closes 26 Dec | ||
SME | Closes 30 Dec | ||
Regular | - | ||
Regular | - | ||
Regular | - |
Bid/Offer Launch date | November 09, 2020 |
Bid/Offer Last date | November 11, 2020 |
Basis of Allotment finalization date | November 17, 2020 |
Initiation of Refunds | November 18, 2020 |
Credit of Shares to Demat Acct | November 19, 2020 |
IPO Shares Listing Date | November 20, 2020 |
Incorporated in 1978, Gland Pharma is one of the largest and fastest-growing injectable-focused companies in the United States of America from 2014-2019. The company has a portfolio of injectable products across various therapeutic areas and delivery systems.
It has a presence in sterile injectables, oncology and ophthalmics, and focuses on complex injectables, NCE-1s, First-to-File products and 505(b) (2) filings. It sells its products through a business-to-business (B2B) model in more than 60 countries across the globe (as of June 30, 2020). The list of countries includes the United States, Europe, Canada, Australia, India, etc.
Gland Pharma has seven manufacturing facilities in India, comprising four finished formulations facilities with a total of 22 production lines and three API facilities. It has a track record of operating a B2B model with some leading pharmaceutical companies like Sagent Pharmaceuticals Inc., Apotex Inc., Fresenius Kabi USA LLC, Athenex Pharmaceutical Division LLC (US), etc. This B2B model is complemented by a business-to-customer (B2C) model in India – the home market of Gland Pharma, leveraging its brand strength and sales network.
Gland Pharma Limited proposes to utilize the net proceeds from this issue towards the following objects:
Here is a quick look at some important information about Gland Pharma:
30-Jun-20 |
31-Mar-20 |
31-Mar-19 |
31-Mar-18 |
|
Total Assets |
4,691.27 |
4,086.04 |
3,523.55 |
2,929.47 |
Total Income |
916.29 (3-month) |
2,772.41 |
2,129.77 |
1,671.68 |
Total Expenses |
496.29 (3-month) |
1,779.54 |
1,423.49 |
1,170.22 |
Profit After Tax |
313.59 (3-month) |
772.86 |
451.86 |
321.05 |
All amounts in INR Crore
Summing Up
As you can see from the financial records, Gland Pharma has posted strong growth in revenues over the last three years. It has been consistent in its performance with strong fundamentals. Before you invest, ensure that you read through the company’s financials and the Red Herring Prospectus (RHP) carefully.
Happy Investing!